Related Experiment Video
Updated: Apr 3, 2026
07:27
Robotics in Surgery: A Modular Robotic Platform Driven Gastric Wedge Resection
Published on: February 7, 2025
1.4K
The Robotic Interval Surgery, A Game-Changer in Optimal Debulking for Ovarian Cancer: A Systematic Review and
Amanda Jessie Maharani1, Pricillia Laurenza Salsabila1, Najla Istyari Radina1
1Undergraduate Medical Education Program, Faculty of Medicine, Universitas Padjadjaran, Bandung, West Java, Indonesia.
Oncotargets and Therapy
|April 2, 2026
Summary
Robotic interval debulking surgery (robotic IDS) improves surgical outcomes for ovarian cancer patients by enhancing complete cytoreduction and reducing blood loss and hospital stays. While operative time is longer, robotic IDS shows promise for advanced-stage and recurrent disease.
Area of Science:
- Gynecologic Oncology
- Surgical Robotics
- Evidence-Based Medicine
Background:
- Ovarian cancer management often requires complex surgical debulking.
- Minimally invasive techniques are increasingly explored to improve surgical outcomes.
- Robotic surgery offers potential advantages in precision and visualization for gynecologic procedures.
Purpose of the Study:
- To evaluate the role of robotic interval debulking surgery (robotic IDS) versus traditional laparotomy in ovarian cancer.
- To compare surgical outcomes and complication rates between robotic IDS and laparotomy.
- To assess the impact of robotic IDS on cytoreduction, blood loss, and hospital stay.
Main Methods:
- A systematic literature review following PRISMA guidelines was conducted.
- Studies published between 2014 and 2024 were searched across major databases.
- Four studies involving 166 patients were included and analyzed using random-effects meta-analysis.
Main Results:
- Robotic IDS significantly improved complete cytoreduction rates (OR 6.67) and reduced estimated blood loss (SMD -0.71) and hospital stay (SMD -1.58).
- No significant differences were observed in intraoperative (OR 0.82) or postoperative complications (OR 0.40).
- Operative time was longer with robotic IDS (SMD 0.40) compared to laparotomy.
Conclusions:
- Robotic IDS is a valuable tool for surgical management of advanced-stage and recurrent ovarian cancer.
- It offers benefits in cytoreduction, blood loss, and hospital stay.
- Further research is warranted to confirm long-term clinical benefits and optimize its application.
